See more : Japan Ecosystem Co., Ltd. (9249.T) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Starry Pharmaceutical Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Acelon Chemicals & Fiber Corporation (1466.TW) Income Statement Analysis – Financial Results
- Dolat Algotech Limited (DOLATALGO.BO) Income Statement Analysis – Financial Results
- ASSA ABLOY AB (publ) (ASAZY) Income Statement Analysis – Financial Results
- M M Forgings Limited (MMFL.NS) Income Statement Analysis – Financial Results
- Halfords Group plc (HFD.L) Income Statement Analysis – Financial Results
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.starrypharm.com
About Zhejiang Starry Pharmaceutical Co.,Ltd.
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products comprise levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is based in Xianju, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.20B | 2.13B | 2.00B | 1.37B | 1.31B | 890.47M | 710.94M | 672.95M | 695.66M | 658.48M | 685.90M | 574.71M | 506.58M |
| Cost of Revenue | 1.66B | 1.62B | 1.25B | 765.73M | 749.66M | 530.06M | 444.29M | 416.24M | 437.17M | 451.02M | 503.52M | 432.63M | 345.20M |
| Gross Profit | 533.33M | 512.45M | 747.98M | 601.36M | 559.18M | 360.41M | 266.65M | 256.70M | 258.49M | 207.47M | 182.39M | 142.08M | 161.38M |
| Gross Profit Ratio | 24.29% | 24.04% | 37.40% | 43.99% | 42.72% | 40.47% | 37.51% | 38.15% | 37.16% | 31.51% | 26.59% | 24.72% | 31.86% |
| Research & Development | 134.56M | 132.61M | 124.58M | 87.84M | 77.78M | 66.13M | 53.13M | 49.06M | 40.39M | 31.52M | 31.36M | 27.86M | 0.00 |
| General & Administrative | 51.24M | 68.80M | 52.82M | 70.35M | 49.70M | 44.53M | 27.30M | 23.59M | 18.24M | 17.92M | 13.07M | 14.87M | 58.51M |
| Selling & Marketing | 91.28M | 70.81M | 22.60M | 11.54M | 13.14M | 11.55M | 9.71M | 16.34M | 11.56M | 9.88M | 9.99M | 11.32M | 9.33M |
| SG&A | 142.52M | 139.61M | 75.42M | 81.89M | 62.85M | 56.08M | 37.01M | 39.93M | 29.80M | 27.80M | 23.07M | 26.19M | 67.84M |
| Other Expenses | 207.05M | 68.33M | 67.84M | 66.33M | 72.42M | -8.11M | -3.38M | 5.52M | -307.74K | 7.51M | 4.58M | 5.12M | 959.00K |
| Operating Expenses | 484.14M | 340.56M | 267.84M | 236.07M | 213.04M | 175.27M | 137.32M | 141.13M | 124.94M | 99.16M | 84.54M | 78.66M | 69.87M |
| Cost & Expenses | 2.15B | 1.96B | 1.52B | 1.00B | 962.70M | 705.33M | 581.61M | 557.37M | 562.11M | 550.17M | 588.06M | 511.29M | 415.08M |
| Interest Income | 7.55M | 9.70M | 5.70M | 3.92M | 1.95M | 3.04M | 670.20K | 777.22K | 423.31K | 711.98K | 599.48K | 619.09K | -0.30 |
| Interest Expense | 108.65M | 92.60M | 73.82M | 92.04M | 82.61M | 64.99M | 34.40M | 24.60M | 36.86M | 32.00M | 27.60M | 24.93M | 13.55M |
| Depreciation & Amortization | 179.55M | 168.93M | 159.09M | 129.09M | 112.05M | 87.36M | 74.06M | 66.56M | 57.78M | 50.94M | 43.54M | 36.23M | 24.12M |
| EBITDA | 327.92M | 312.87M | 628.70M | 524.49M | 417.01M | 270.67M | 211.99M | 189.85M | 188.01M | 162.79M | 144.94M | 102.87M | 115.62M |
| EBITDA Ratio | 14.93% | 14.68% | 32.00% | 38.57% | 33.61% | 30.91% | 30.05% | 28.26% | 27.51% | 25.20% | 21.40% | 18.12% | 23.18% |
| Operating Income | 138.93M | 152.43M | 399.77M | 401.06M | 330.97M | 126.83M | 106.87M | 93.42M | 93.68M | 75.02M | 70.70M | 37.29M | 77.24M |
| Operating Income Ratio | 6.33% | 7.15% | 19.99% | 29.34% | 25.29% | 14.24% | 15.03% | 13.88% | 13.47% | 11.39% | 10.31% | 6.49% | 15.25% |
| Total Other Income/Expenses | -83.60M | -217.83M | -45.73M | 9.76M | -109.08M | -55.92M | -3.38M | -18.21M | -36.77M | -27.98M | -23.67M | -22.46M | 172.92K |
| Income Before Tax | 55.33M | -65.40M | 395.39M | 303.70M | 221.90M | 118.72M | 103.49M | 97.45M | 93.37M | 79.85M | 73.81M | 41.72M | 77.41M |
| Income Before Tax Ratio | 2.52% | -3.07% | 19.77% | 22.22% | 16.95% | 13.33% | 14.56% | 14.48% | 13.42% | 12.13% | 10.76% | 7.26% | 15.28% |
| Income Tax Expense | 798.82K | 6.52M | 65.62M | 50.10M | 38.98M | 23.18M | 22.07M | 21.54M | 19.91M | 12.82M | 11.01M | 6.72M | 10.08M |
| Net Income | 44.23M | -71.93M | 323.75M | 238.73M | 170.33M | 93.68M | 83.12M | 76.12M | 68.94M | 67.70M | 63.66M | 35.78M | 67.57M |
| Net Income Ratio | 2.01% | -3.37% | 16.19% | 17.46% | 13.01% | 10.52% | 11.69% | 11.31% | 9.91% | 10.28% | 9.28% | 6.23% | 13.34% |
| EPS | 0.13 | -0.21 | 0.95 | 0.71 | 0.52 | 0.29 | 0.25 | 0.25 | 0.28 | 0.27 | 0.26 | 0.15 | 0.27 |
| EPS Diluted | 0.13 | -0.21 | 0.95 | 0.71 | 0.52 | 0.29 | 0.25 | 0.25 | 0.28 | 0.27 | 0.26 | 0.15 | 0.27 |
| Weighted Avg Shares Out | 340.25M | 342.25M | 341.94M | 334.22M | 328.58M | 327.87M | 329.28M | 307.17M | 245.69M | 247.71M | 246.02M | 245.44M | 247.21M |
| Weighted Avg Shares Out (Dil) | 340.25M | 342.25M | 341.94M | 334.22M | 328.58M | 327.87M | 330.54M | 307.17M | 245.69M | 247.71M | 246.02M | 245.48M | 247.21M |
Source: https://incomestatements.info
Category: Stock Reports